ArticleJournal of immunology (Baltimore, Md. : 1950)2026
Exacerbation of inflammatory bone loss in TET2-driven clonal hematopoiesis.
Article in Journal of immunology (Baltimore, Md. : 1950), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Clonal hematopoiesis of indeterminate potential (CHIP) arises from age-related somatic mutations in hematopoietic stem cells in the bone marrow (BM), driving clonal expansion and altered phenotypes. Loss-of-function mutations in the epigenetic regulator TET2 are among the most frequent in CHIP and increase the risk of hematologic malignancies and chronic inflammatory disorders. Here, we investigated the impact of TET2-driven CHIP on inflammatory bone loss. Partial BM reconstitution with TET2-deficient (Tet2-/-) cells promoted clonal expansion and spontaneous periodontitis, characterized by gingival inflammation and alveolar bone loss. Furthermore, mice with TET2-driven CHIP exhibited heightened susceptibility to experimentally induced bone loss, including ligature-induced periodontitis and collagen antibody-induced arthritis. This inflammatory bone loss phenotype was associated with increased tissue infiltration of hyperinflammatory Tet2-/- neutrophils and monocytes, elevated IL-17-producing CD4⁺ T cells (Th17), and enhanced osteoclastogenesis driven by paracrine signals from Tet2-/- myeloid cells acting on wild-type osteoclast precursors. Although T cell-intrinsic TET2 deficiency minimally affected Th17 differentiation in vitro, Tet2-/- dendritic cells exhibited enhanced capacity to drive Th17 differentiation from wild-type CD4⁺ T cells. These findings reveal mechanistic links between TET2-driven CHIP and the pathogenesis of inflammatory bone loss disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.